Subscribe
shutterstock_1919150828_margarett24
Margarett24 / Shutterstock.com
13 October 2022Big PharmaMuireann Bolger

Pharma company raises pressure with hypotension drug lawsuit

Nexus raises second complaint against same parties in a month | Ready-to-use drug that can raise the blood pressure of hypotension patients at issue.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
Nexus and Nevakar face off over hypotension drug
19 August 2021   Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
FDA approves milestone biosimilar insulin drug
29 July 2021   The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.


Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024

Editor's picks

Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Americas
Litigation implications of the USPTO’s terminal disclaimer proposal
29 August 2024
Europe
UPC confirms validity of Edwards Lifesciences heart valve tech patent
23 July 2024
Europe
Labour govt appoints new Minister with IP oversight
9 July 2024
Americas
New-look WIPR Leaders 2024 is ‘most rigorous’ yet
2 July 2024
Americas
Earthquake Chevron: A massive shock to the system?
2 July 2024

More on this story

Americas
Nexus and Nevakar face off over hypotension drug
19 August 2021   Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
FDA approves milestone biosimilar insulin drug
29 July 2021   The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

More on this story

Americas
Nexus and Nevakar face off over hypotension drug
19 August 2021   Nexus Pharmaceuticals and rival Nevakar have gone to court to determine which company has the right to sell a new hypotension drug, which can be administered to patients under anesthesia during surgery.
Americas
FDA approves milestone biosimilar insulin drug
29 July 2021   The US Food and Drug Administration has approved the first-ever interchangeable biosimilar product, an insulin treatment for Types 1 and 2 diabetes.

More features

Gilead scores win in fake HIV drug dispute
Polsinelli grows roster with ex-corporate counsel
‘Don’t rely on national case law’ at the UPC: Wouter Pors, Bird & Bird
Sandoz wins $137.2m payout for lost profits in generic launch
Sanofi signs global rights deal to develop rare cancer therapy
Unified Patent Court visualised: Cases, divisions, and classes in charts
WBD to merge with firm to create ‘powerhouse’ practice
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers